WO2011133729A3 - Anti-viral compounds - Google Patents

Anti-viral compounds Download PDF

Info

Publication number
WO2011133729A3
WO2011133729A3 PCT/US2011/033338 US2011033338W WO2011133729A3 WO 2011133729 A3 WO2011133729 A3 WO 2011133729A3 US 2011033338 W US2011033338 W US 2011033338W WO 2011133729 A3 WO2011133729 A3 WO 2011133729A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
viral compounds
rig
pathway
viral infection
Prior art date
Application number
PCT/US2011/033338
Other languages
French (fr)
Other versions
WO2011133729A2 (en
Inventor
Shawn P. Iadonato
Kristin Bedard
Original Assignee
Kineta, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta, Inc. filed Critical Kineta, Inc.
Priority to US13/642,822 priority Critical patent/US8895608B2/en
Priority to EP11772681.0A priority patent/EP2560636A4/en
Priority to JP2013506290A priority patent/JP2013525368A/en
Publication of WO2011133729A2 publication Critical patent/WO2011133729A2/en
Publication of WO2011133729A3 publication Critical patent/WO2011133729A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
PCT/US2011/033338 2010-04-23 2011-04-20 Anti-viral compounds WO2011133729A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/642,822 US8895608B2 (en) 2010-04-23 2011-04-20 Sulfonamide anti-viral compounds
EP11772681.0A EP2560636A4 (en) 2010-04-23 2011-04-20 Anti-viral compounds
JP2013506290A JP2013525368A (en) 2010-04-23 2011-04-20 Antiviral compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32757110P 2010-04-23 2010-04-23
US61/327,571 2010-04-23

Publications (2)

Publication Number Publication Date
WO2011133729A2 WO2011133729A2 (en) 2011-10-27
WO2011133729A3 true WO2011133729A3 (en) 2012-03-15

Family

ID=44834799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033338 WO2011133729A2 (en) 2010-04-23 2011-04-20 Anti-viral compounds

Country Status (5)

Country Link
US (1) US8895608B2 (en)
EP (1) EP2560636A4 (en)
JP (1) JP2013525368A (en)
TW (1) TWI522353B (en)
WO (1) WO2011133729A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR102074089B1 (en) 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 Multicyclic compounds and methods of use thereof
JP2014501790A (en) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ， インコーポレイテッド Process for the preparation of isoquinolinone and solid form of isoquinolinone
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6449845B2 (en) 2013-03-15 2019-01-09 クロモセル コーポレイション Sodium channel modulator for the treatment of pain
KR20160054570A (en) 2013-09-10 2016-05-16 크로모셀 코포레이션 Sodium channel modulators for the treatment of pain and diabetes
ES2968371T3 (en) 2013-10-10 2024-05-09 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
KR102103256B1 (en) 2013-10-14 2020-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Selectively substituted quinoline compounds
KR102365952B1 (en) 2013-10-14 2022-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 Selectively substituted quinoline compounds
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
DK3484528T3 (en) 2016-07-18 2021-02-15 Janssen Pharmaceutica Nv ROPE PET IMAGE FORMATION LIGANDER
EA201990400A1 (en) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. COMPOUNDS AND COMPOSITIONS AND THEIR APPLICATION
MA45795A (en) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS, AND ASSOCIATED USES
KR102605854B1 (en) 2017-02-16 2023-11-23 선오비온 파마슈티컬스 인코포레이티드 Treatment methods for schizophrenia
JOP20200001A1 (en) 2017-07-11 2022-10-30 Vertex Pharma Carboxamides as modulators of sodium channels
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
MX2020008537A (en) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof.
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CN115734785A (en) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S) - (4, 5-dihydro-7H-thieno [2,3-c ] pyran-7-yl) -N-methylmethanamine for the treatment of neurological and psychiatric disorders
CN112851633B (en) * 2021-01-19 2021-12-07 上海应用技术大学 2-aminothiophene neuraminidase inhibitor and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541381B2 (en) * 2002-02-19 2009-06-02 Northwestern University Non-covalent inhibitors of AmpC β-lactamase
WO2010013071A2 (en) * 2008-08-01 2010-02-04 University Court Of The University Of Dundee Methods concerning ppar delta and antagonists thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
SI1560827T1 (en) * 2002-11-01 2011-04-29 Abbott Lab Anti-infective agents
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
AU2008282903B2 (en) * 2007-07-30 2011-06-30 Encysive Pharmaceuticals, Inc. Modulators of CCR9 receptor and methods of use thereof
US8779001B2 (en) * 2008-06-04 2014-07-15 The United States of America National Institute of Health (NIH) Stat3 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541381B2 (en) * 2002-02-19 2009-06-02 Northwestern University Non-covalent inhibitors of AmpC β-lactamase
WO2010013071A2 (en) * 2008-08-01 2010-02-04 University Court Of The University Of Dundee Methods concerning ppar delta and antagonists thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IRENE PATERNITI ET AL.: "Evidence for the Role of Peroxisome Proliferator-Activated REceptor-beta/delta in the Development of Spinal Cord Injury.", JOURNA1 OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS., vol. 333, no. 2, 22 February 2010 (2010-02-22), pages 465 - 477 *
See also references of EP2560636A4 *

Also Published As

Publication number Publication date
WO2011133729A2 (en) 2011-10-27
EP2560636A2 (en) 2013-02-27
JP2013525368A (en) 2013-06-20
EP2560636A4 (en) 2013-11-27
TW201141853A (en) 2011-12-01
US20130039945A1 (en) 2013-02-14
TWI522353B (en) 2016-02-21
US8895608B2 (en) 2014-11-25

Similar Documents

Publication Publication Date Title
WO2011133722A3 (en) Anti-viral compounds
WO2011133728A3 (en) Anti-viral compounds
WO2013049352A3 (en) Anti-viral compounds
WO2011133729A3 (en) Anti-viral compounds
WO2011133727A3 (en) Anti-viral compounds
WO2013049407A3 (en) Anti-viral compounds
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
WO2014052836A3 (en) Methods and compositions for treating infection
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2013119916A3 (en) Compounds for treating spinal muscular atrophy
WO2013075083A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2011133707A3 (en) Anti-viral compounds
WO2013120104A3 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013026740A3 (en) Methods and means to modify a plant genome
WO2012083048A3 (en) Anti-viral compounds
WO2012068589A3 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012083053A3 (en) Anti-viral compounds
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2012083061A3 (en) Anti-viral compounds
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
WO2012103810A1 (en) Certain chemical entities, compositions, and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772681

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013506290

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13642822

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011772681

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011772681

Country of ref document: EP